157 related articles for article (PubMed ID: 24784346)
21. Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma.
Coosemans A; Wölfl M; Berneman ZN; Van Tendeloo V; Vergote I; Amant F; Van Gool SW
Anticancer Res; 2010 Sep; 30(9):3709-14. PubMed ID: 20944158
[TBL] [Abstract][Full Text] [Related]
22. Identification of a WT1 protein-derived peptide, WT1, as a HLA-A 0206-restricted, WT1-specific CTL epitope.
Li Z; Oka Y; Tsuboi A; Fujiki F; Harada Y; Nakajima H; Masuda T; Fukuda Y; Kawakatsu M; Morimoto S; Katagiri T; Tatsumi N; Hosen N; Shirakata T; Nishida S; Kawakami Y; Udaka K; Kawase I; Oji Y; Sugiyama H
Microbiol Immunol; 2008 Nov; 52(11):551-8. PubMed ID: 19090835
[TBL] [Abstract][Full Text] [Related]
23. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
24. WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report.
Dohi S; Ohno S; Ohno Y; Takakura M; Kyo S; Soma G; Sugiyama H; Inoue M
Anticancer Res; 2011 Jul; 31(7):2441-5. PubMed ID: 21873157
[TBL] [Abstract][Full Text] [Related]
25. [Efficacy of WT1 peptide-/MUC-1 peptide-pulsed dendritic cell therapy in 313 patients with a wide range of cancers].
Kato Y
Gan To Kagaku Ryoho; 2014 Oct; 41(10):1280-2. PubMed ID: 25335717
[TBL] [Abstract][Full Text] [Related]
26. Identification and analysis of mutations in WTX and WT1 genes in peripheral blood and tumor tissue of children with Wilms' tumor.
Wang H; Shen Y; Sun N; Jiang YP; Li ML; Sun L
Chin Med J (Engl); 2012 May; 125(10):1733-9. PubMed ID: 22800892
[TBL] [Abstract][Full Text] [Related]
27. Impact of dendritic cell vaccines pulsed with Wilms' tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers.
Takahashi H; Okamoto M; Shimodaira S; Tsujitani S; Nagaya M; Ishidao T; Kishimoto J; Yonemitsu Y;
Eur J Cancer; 2013 Mar; 49(4):852-9. PubMed ID: 23245331
[TBL] [Abstract][Full Text] [Related]
28. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063
[TBL] [Abstract][Full Text] [Related]
29. Dendritic cell immunotherapy in uterine cancer.
Coosemans A; Tuyaerts S; Vanderstraeten A; Vergote I; Amant F; Van Gool SW
Hum Vaccin Immunother; 2014; 10(7):1822-7. PubMed ID: 25424788
[TBL] [Abstract][Full Text] [Related]
30. The Wilms' tumor antigen is a novel target for human CD4+ regulatory T cells: implications for immunotherapy.
Lehe C; Ghebeh H; Al-Sulaiman A; Al Qudaihi G; Al-Hussein K; Almohareb F; Chaudhri N; Alsharif F; Al-Zahrani H; Tbakhi A; Aljurf M; Dermime S
Cancer Res; 2008 Aug; 68(15):6350-9. PubMed ID: 18676860
[TBL] [Abstract][Full Text] [Related]
31. WT1 peptide vaccine for the treatment of cancer.
Oka Y; Tsuboi A; Oji Y; Kawase I; Sugiyama H
Curr Opin Immunol; 2008 Apr; 20(2):211-20. PubMed ID: 18502632
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy in Acute Leukemias: Implications and Perspectives Using Wt1 Antigen.
Cebinelli GC; DE Sousa Pereira N; Sena MM; DE Oliveira CE; Fujita TC; DA Rocha SP; DE Abreu Oliveira FJ; Marinello PC; Watanabe MA
Anticancer Res; 2016 Aug; 36(8):3795-802. PubMed ID: 27466479
[TBL] [Abstract][Full Text] [Related]
33. Generation and Cryopreservation of Clinical Grade Wilms' Tumor 1 mRNA-Loaded Dendritic Cell Vaccines for Cancer Immunotherapy.
Smits EL; Stein B; Nijs G; Lion E; Van Tendeloo VF; Willemen Y; Anguille S; Berneman ZN
Methods Mol Biol; 2016; 1393():27-35. PubMed ID: 27033213
[TBL] [Abstract][Full Text] [Related]
34. WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone.
Nakajima H; Kawasaki K; Oka Y; Tsuboi A; Kawakami M; Ikegame K; Hoshida Y; Fujiki F; Nakano A; Masuda T; Wu F; Taniguchi Y; Yoshihara S; Elisseeva OA; Oji Y; Ogawa H; Azuma I; Kawase I; Aozasa K; Sugiyama H
Cancer Immunol Immunother; 2004 Jul; 53(7):617-24. PubMed ID: 15175906
[TBL] [Abstract][Full Text] [Related]
35. [Cancer antigen WT1-targeting treatment for the malignancies].
Oka Y; Kawase I
Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):375-82. PubMed ID: 18974621
[TBL] [Abstract][Full Text] [Related]
36. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues.
Tsuboi A; Oka Y; Udaka K; Murakami M; Masuda T; Nakano A; Nakajima H; Yasukawa M; Hiraki A; Oji Y; Kawakami M; Hosen N; Fujioka T; Wu F; Taniguchi Y; Nishida S; Asada M; Ogawa H; Kawase I; Sugiyama H
Cancer Immunol Immunother; 2002 Dec; 51(11-12):614-20. PubMed ID: 12439606
[TBL] [Abstract][Full Text] [Related]
37. Th1-biased humoral immune responses against Wilms tumor gene WT1 product in the patients with hematopoietic malignancies.
Wu F; Oka Y; Tsuboi A; Elisseeva OA; Ogata K; Nakajima H; Fujiki F; Masuda T; Murakami M; Yoshihara S; Ikegame K; Hosen N; Kawakami M; Nakagawa M; Kubota T; Soma T; Yamagami T; Tsukaguchi M; Ogawa H; Oji Y; Hamaoka T; Kawase I; Sugiyama H
Leukemia; 2005 Feb; 19(2):268-74. PubMed ID: 15538407
[TBL] [Abstract][Full Text] [Related]
38. EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity.
Scharnhorst V; Menke AL; Attema J; Haneveld JK; Riteco N; van Steenbrugge GJ; van der Eb AJ; Jochemsen AG
Oncogene; 2000 Feb; 19(6):791-800. PubMed ID: 10698497
[TBL] [Abstract][Full Text] [Related]
39. The WT1 gene--its role in tumourigenesis and prospects for immunotherapeutic advances.
Lindstedt I; Lindgren MA; Andersson E; Engström W
In Vivo; 2014; 28(5):675-81. PubMed ID: 25189877
[TBL] [Abstract][Full Text] [Related]
40. Sensitive detection of rare antigen-specific T cells directed against Wilms' tumor 1 by FluoroSpot assay.
Danielzik T; Koldehoff M; Buttkereit U; Beelen DW; Horn PA; Lindemann M
Leuk Lymphoma; 2018 Feb; 59(2):490-492. PubMed ID: 28573960
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]